Previous studies have indicated primary prophylactic G-CSF for elderly breast cancer patients to be effective in reducing FN incidence (24% to 6%), reducing the number of patients with clinically significant dose delays (21% to 14%) or dose reductions (32% to 15%), and even increasing the number chemotherapy cycles administered (by 2%) [31,32]. Here, CSF3 is linked to breast cancer.